Ceretas LtdASX: CTS

Phase 2 CERE-CALM trial expands into Victoria

· Issued by Ceretas Ltd via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

This expansion broadens the clinical trial network, enhancing patient recruitment opportunities across Australia. The company expects to commence treatment for the first patient in the coming weeks, following successful enrolment. The trial evaluates low-intensity focused ultrasound as a potential treatment for behavioral and psychological symptoms of dementia in Alzheimer's patients.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Announcement Phase 2 CERE-CALM trial expands into Victoria § Ethics approval secured for Goulburn Valley Hospital in Victoria, expanding the Phase 2 CERE-CALM clinical trial beyond New South Wales for the first time § Expanded clinical trial network to support patient recruitment, with...

Ceretas Ltd on 6ix

Earlier from Ceretas

Later from Ceretas

All Ceretas news releases